...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
【24h】

Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.

机译:发现新的转化生长因子-βI型受体(ALK5)抑制剂的药理学模型和虚拟筛选。

获取原文
获取原文并翻译 | 示例
           

摘要

Inhibitors of transforming growth factor-beta Type I Receptor (ALK5) have been thought as potential drugs for the treatment of fibrosis and cancer and a considerable number of ALK5 inhibitors have been reported recently. In order to clarify the essential structure-activity relationship for the known ALK5 inhibitors as well as identify new lead compounds against ALK5, 3D pharmacophore models have been established based on the known ALK5 inhibitors. The best pharmacophore model, Hypo1, was used as a 3D search query to perform a virtual screening. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking studies to refine the retrieved hits. Finally a total of 100 compounds were obtained and some of them were selected for further in vitro and in vivo assay studies.
机译:转化生长因子-βI型受体(ALK5)的抑制剂被认为是治疗纤维化和癌症的潜在药物,最近已报道了许多ALK5抑制剂。为了阐明已知ALK5抑制剂的基本结构-活性关系以及鉴定针对ALK5的新的先导化合物,已基于已知ALK5抑制剂建立了3D药效团模型。最好的药效团模型Hypo1被用作3D搜索查询以执行虚拟筛选。命中化合物随后按照Lipinski的5条法则进行过滤,并进行对接研究以完善检索到的命中。最终获得了总共100种化合物,并选择了其中一些用于进一步的体外和体内测定研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号